Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
OwnerPhilip LAKE, Claudy Mulloninventors
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.
Claims11
1-21. (canceled)
A pharmaceutical combination comprising:
- a) 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in pharmaceutically acceptable salt form;
- b) basiliximab, and c) 40-O-(2-hydroxyethyl)-rapamycin.
A method for the treatment or prophylaxis of insulin-producing cell graft rejection in an insulin-producing cell graft recipient comprising co-administering to the recipient an effective amount of an ALH agent and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone, and a soluble human complement inhibitor.
Dependencies are inferred from the claim text.